Archive: September 2022
Feature Article
How We Manage Idiopathic Multicentric Castleman Disease
Overview • We recommend first-line treatment with anti–interleukin 6 (anti–IL-6) for all patients with idiopathic multicentric Castleman disease. • We recommend enrollment of all patients with […]
Feature Article
A Narrative Review of Anti–SARS-CoV-2 Vaccines and Immune Thrombocytopenia: Be Aware, But Reassured
Abstract: Background: The COVID-19 pandemic gave rise to rapid development of anti–SARS-CoV-2 vaccines using established and new technologies. Immune thrombocytopenia (ITP) is a bleeding disorder that […]
How We Manage Grief
Introduction Extensive literature exists on coping with the death of a patient with cancer, with much of the focus on what to say to the patient’s […]
Letter From the Editor
“Degriefing”
In this issue you will find a thoughtful and sobering essay by Drs Anthony Galanos and Matthew Labriola, my colleagues at Duke, called “How We Manage […]
Ovarian Cancer
Maintenance Therapy With PARP Inhibition in Ovarian Cancer
H&O Which poly(ADP-ribose) polymerase (PARP) inhibitors are approved for use as maintenance therapy in ovarian cancer? TH Two PARP inhibitors are approved for use as frontline […]
Advances in LLM
Hyper-CVAD–Based Regimens in Adult Patients With Acute Lymphoblastic Leukemia
H&O How was the hyper-CVAD regimen originally used? EJ The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen was developed by Kantarjian and colleagues at MD […]
Breast Cancer
The Effectiveness of Immune Checkpoint Inhibitors in the Neoadjuvant and Post-Neoadjuvant Breast Cancer Settings
H&O Could you describe the design of the KEYNOTE-522 study? LP KEYNOTE-522 was a large, randomized, placebo-controlled phase 3 trial that tested pembrolizumab (Keytruda, Merck) as […]
Advances in Drug Development
Variability in Global Drug Prices
H&O Why are drug prices in the United States so high? ASK Brand-name drug prices are on average approximately 2 to 4 times higher in the […]